Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1992 Feb;20(1):45-53.
doi: 10.1177/030006059202000106.

Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease

Affiliations
Clinical Trial

Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease

M Lunetta et al. J Int Med Res. 1992 Feb.

Abstract

The aim of the double-blind, crossover, placebo-controlled study was to evaluate whether oral administration of sulodexide, a medium molecular weight glycosaminoglycan, had an effect on whole blood, plasma and serum viscosity, and/or plasma fibrinogen concentrations. The drug was administered orally at a dose of 500 lipoproteinlipase releasing units twice daily for 1 month to two groups of 20 patients with peripheral vascular disease; one group was administered a placebo--drug sequence and the other a drug--placebo sequence. Orally administered sulodexide had a marked effect on plasma viscosity and on plasma fibrinogen concentrations, whereas there were no effects on whole blood viscosity. No significant side-effects were observed. The fact that sulodexide was highly effective, even after oral administration, suggests it may be useful for the treatment of patients with atheromatous vascular diseases of the lower limbs requiring chronic therapy.

PubMed Disclaimer

Publication types

LinkOut - more resources